At a glance
ClinicalIndex Comparison RecordN/ACompleted· 43 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 6
- ✓Relapsing form of MS, age 18–65 years at informed consent
- ✓Stable natalizumab dose for ≥12 consecutive months
- ✓No evidence of natalizumab disease activity (clinical or MRI) for 6 months prior to screening
- ✓Ocrelizumab-naïve
Key exclusion· 12
- ✕History of primary or secondary progressive multiple sclerosis
- ✕Active hepatitis B infection at screening
- ✕Untreated hepatitis C or tuberculosis
- ✕History of progressive multifocal leukoencephalopathy (PML) or HIV-positive status
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
In Brief
An observational study for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 43 participants across 5 sites.
Detailed Summary
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionJan 2022
Study CompletionJun 2022
TodayJul 2026
First PostedMay 17, 2017
Enrollment StartJun 1, 2017
Primary CompletionJan 28, 2022
Study CompletionJun 6, 2022
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.1 years ago